ADMEDUS LIMITED - FUTURE TAKES SHAPE WITH US LAUNCH OF CARDIOCEL 3D®
01.02.18
NEWS RELEASE
FUTURE TAKES SHAPE WITH US LAUNCH OF CARDIOCEL 3D®
Today marks a significant milestone for Admedus Limited (ASX:AHZ), and our ADAPT® technology, with the official launch in North America of our first shaped tissue product, CardioCel 3D®.
Offering patients the long-term health benefits of our clinically-superior ADAPT® technology, CardioCel 3D® is at the cutting-edge of cardiovascular science; its unique pre-shaped curve provides physicians immediate access to a clinically-superior, off-the-shelf, optimised arch reconstruction solution with non-antigenic response and unique calcification resistance.
“CardioCel 3D® represents a disruptive technology in the high-complexity congenital defect repair space. Current alternative products are limited in their abilities to meet all patient and physician needs, often requiring compromises in terms of clinical benefit and outcome,” said Admedus CEO Wayne Paterson.
“With CardioCel 3D® such trade-offs are not required; surgeons can achieve a more natural shape, allowing for optimal compliance and dynamics, while simultaneously providing the superior clinical benefits of our ADAPT® technology to deliver transformative healing.”
“The launch of CardioCel 3D® in North America is also an exciting commercial opportunity for Admedus as we continue to move up the value chain, building momentum and credibility as a bankable medical technology business,” he added.
To support the launch, Admedus representatives participated in the 54th Society of Thoracic Surgeons Annual Meeting (STS) 27-31 January in Florida where they had the opportunity to introduce CardioCel 3D® and discuss the growing body of evidence that shape matters in complex arch repair with world-leading cardiothoracic surgeons.
This follows extensive user-evaluation testing1 and demonstrates our determination to be at the forefront of health innovation; delivering superior solutions, backed by world-leading science to help physicians make a real difference in the lives of their patients.
Background:
ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Our clinically superior ADAPT® products are the only ones to have achieved nine years without calcification or degradation.
With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life. All Admedus ADAPT® products are manufactured in, and distributed from, our state-of-the-art biomanufacturing facility in Australia.
CardioCel 3D® is an implantable medical device and is only available on the recommendation of a suitable qualified healthcare professional in the United States where it has been approved for sale and use.
mce-anchor1 In November 2017, CardioCel 3D® completed a comprehensive user-evaluation program that provided extensive clinical data and gained positive feedback from surgeons at seven key reference sites across North America and Australia.
ENDS
About Admedus Limited
Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
(20min delay)